BackTable Urology

How can you use social media to educate, empower, and inspire as a physician while staying true to your professional values? On this episode of BackTable Urology, guest host Dr. Maheetha Bharadwaj talks with Dr. Rena Malik and Dr. Fenwa Milhouse about building an authentic online presence that educates, inspires, and connects. The conversation highlights the power of visibility, the challenges of professional boundaries and misinformation, and the potential for social media to expand both patient outreach and career opportunities.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps

00:00 - Introduction
04:17 - Getting Started on Social Media
12:24 - Finding Your Niche
17:04 - Being a Woman in Urology
18:40 - Impact On Patient Care
23:59 - Doctor-Patient Boundaries
28:33 - Social Media Pitfalls
38:53 - Creator Monetization
45:58 - Advice for New Creators

---

More about this episode

They share insights from years of content creation, including tips for getting started, finding your niche, and balancing clinical work with online engagement. The discussion covers issues unique to women in urology, the impact of social media on patient care and doctor-patient boundaries, how to avoid burnout, and strategies for monetization and staying true to your message. The episode wraps up with practical advice for new creators and reflections on the privilege and responsibility of inspiring future urologists.

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

Hypospadias can be surgically corrected early in life, but many patients drop out of care before puberty or adulthood, leaving important urinary and sexual health concerns unaddressed. On this episode of BackTable Urology, Dr. Arthi Hannallah and Dr. Nicco Passoni talk with Dr. Vinaya Bhatia about improving lifelong engagement for people with hypospadias. They highlight advances in surgical technique, the role of research, and how digital tools like the WYSH platform help keep patients and families connected to care.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps
00:00 - Introduction
04:22 - Hypospadias Overview and Symptom Chronology
09:14 - Not A One Size Fits All: Developing WYSH
13:28 - Reengaging Families and Patients
20:04 - Adult Urology Sequelae
25:08 - Demystifying Surgery and Improving Training
34:00 - Centers of Excellence Debate
36:56 - Future Goals and Wrap Up

---

More about this episode
The discussion covers the development and impact of the WYSH platform, strategies for supporting long-term follow-up, and the learning curve of hypospadias surgery. Dr. Bhatia shares insights on better training, the creation of centers of excellence, and the importance of ongoing research and family engagement to improve quality of life at every stage.

---

Resources
Worldwide Yearly Screening for Hypospadias: https://clinicaltrials.gov/study/NCT06966375

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app

Can a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by

Johnson & Johnson

https://www.inlexzohcp.com/

---

Timestamps

00:00 - Introduction
02:40 - Why Focus on TAR-200
05:35 - Device Basics
07:05 - Dosing Schedule Explained
11:17 - SUNRISE-01 Trial Results
15:07 - Patient Selection and Contraindications
20:52 - Indications for Device Removal
23:26 - Clinic Workflow Learning Curve
25:56 - Tips for Insertion and Device Deployment
28:52 - Cystoscopy Findings and Surveillance Protocol
32:16 - Treatment Sequencing
38:43 - Future Trial and Research Directions
45:16 - Biomarkers, AI, and Personalizing Care
46:35 - Cost, Supportive Care, and Patient Burden
48:42 - Closing Thoughts

---

More about this episode

The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr. Psutka discusses dosing schedules, when to remove the device, and how to handle complications like UTI, hematuria, and LUTS. The episode also covers surveillance protocols, the impact on clinic operations, and the importance of balancing vigilant cancer surveillance with patient burden. Finally, they touch on future directions, including biomarkers, AI-assisted pathology, and optimizing the timing of cystectomy and supportive care for a more personalized approach to NMIBC.

---

Resources

TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
https://ascopubs.org/doi/10.1200/JCO-25-01651

SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer

SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-mushttps://www.urotoday.com/conference-highlights/suo-2024/suo-2024-bladder-cancer/156723-suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared-with-intravesical-chemotherapy-after-bacillus-calmette-guerin-in-recurrent-high-risk-non-muscle-invasive-bladder-cancer.htmlcle Invasive Bladder Cancer

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
https://ascopubs.org/doi/10.1200/JCO-25-02382

INLEXZO - SunRISe-3 Study
https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-3-study

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

The definitive treatment for adult acquired buried penis is surgery, but successful treatment depends on having a well-coordinated network of patient support, multidisciplinary care teams, and reconstructive urologic surgery expertise. This episode of Backtable Urology overviews this multifaceted disease and dives into reconstructive surgery techniques, featuring Dr. George Koch and Dr. Paul Rusilko.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps

00:00 - Introduction
04:10 - History of Buried Penis Treatment
08:47 - Grafts Versus Flaps
11:34 - Hidden Pathologies and Informed Consent
13:46 - Research and Insurance Approval
18:24 - Delayed Care and Disease Burden
22:31 - Deciding When to Operate and Temporizing Procedures
30:23 - Building Referral Networks
33:13 - Future Directions
36:42 - Infection Risk
41:15 - Technique Evolution
45:57 - Preop Evaluation Essentials
50:50 - Intraop Keys to Success and Graft Protection
59:26 - Postop Pathway and Teamwork
01:02:54 - W-Plasty Video Walkthrough
01:13:52 - Wrap Up

---

More about this episode

The doctors explore the nuances of surgical treatment, emphasizing the importance of thorough preoperative counseling given the high likelihood of unexpected intraoperative findings and the need to adjust the surgical plan. Dr. Rusilko also discusses the broader burden of disease, including depression, strictures, occult penile cancer, and the high rate of postoperative complications, most of which are low grade. He stresses that earlier referral may improve patient care. The episode concludes with practical surgical tips, guidance on building a buried penis practice, strategies for setting realistic recovery expectations, and an in-depth case review of his novel W-plasty technique.

---

Resources

W-plasty: A novel procedure for the repair of adult-acquired buried penis https://doi.org/10.1016/j.urolvj.2023.100219

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

More neuromodulation options mean more opportunities to personalize care. In this episode, Dr. Ken Peters and Dr. Tracey Wilson join Dr. Jannah Thompson to discuss the latest implantable tibial nerve stimulation and sacral neuromodulation technologies for OAB and UUI. They compare available devices, share practical insights on patient selection, and explore how shared decision making, advanced practice providers, and equitable access influence treatment adoption.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast was developed in collaboration with

Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)

https://sufuorg.com/home.aspx

---

Timestamps

00:00 - Introduction
07:59 - Overview of Nerve Stimulation Therapies
13:22 - Case #1
22:00 - Case #2
28:23 - Nuspera
34:21 - APPs in Practice
39:21 - Reimbursement Roadblocks
47:03 - Multimodal Therapy
49:51 - Case #3
56:06 - Final Advice

---

Resources

Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial
https://www.auajournals.org/doi/10.1016/j.juro.2009.12.036

Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinence
https://neuspera.com/neuspera-medical-announces-12-month-pivotal-trial-results-for-the-companys-integrated-sacral-neuromodulation-system-for-urinary-urge-incontinence/

Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients
https://www.sciencedirect.com/science/article/pii/S0090429520305574?via%3Dihub

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

Can focal therapy truly “thread the needle” between active surveillance and radical prostate cancer treatment? In this episode of BackTable Urology, host Dr. Tiwa Akinsola is joined by Dr. George Schade from the University of Washington to explore focal therapy as a middle ground between active surveillance and radical treatments. Dr. Schade reviews non-radiation energy modalities including HIFU, TULSA/HI-DU, cryotherapy, and irreversible electroporation, highlighting patient selection, institutional experience, technical nuances, and quality-of-life outcomes from recent trials.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps
00:00 - Introduction
02:09 - Overview of Focal Therapy Modalities
04:46 - Deciding Between HIFU and IRE
06:56 - Evidence and Trials
09:40 - Counseling Patients on Outcomes
12:09 - Building a Focal Therapy Program
16:12 - Navigating Insurance and Appeals
21:48 - Managing Large Glands And TURP
25:12 - Preop Workup Essentials and OR Workflow
32:32 - Overcoming the Learning Curve
35:52 - PostOp Recovery and Surveillance
39:04 - Options for Managing Recurrence
42:44 - Challenges with Repeat Ablation
44:56 - Final Takeaways

---

More about this episode
The conversation covers candidate selection and confirmatory biopsy, perioperative technique and recovery, and ongoing surveillance with PSA, MRI, and biopsy. Dr. Schade also discusses challenges with insurance approvals, building a focal therapy practice, and options for managing recurrence, including repeat ablation, surgery, or radiation. The episode examines how to balance cancer control with quality of life and reviews the evolving evidence base supporting focal therapy’s role in prostate cancer treatment.

---

Resources

Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial:
https://www.sciencedirect.com/science/article/pii/S030228382500346X

Focal therapy of localized prostate cancer
https://pubmed.ncbi.nlm.nih.gov/35996758/

Focal Therapy for Prostate Cancer: Available Technologies, Patient Selection, Follow-Up Protocols and Reported Outcomes
https://pubmed.ncbi.nlm.nih.gov/41339218/

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app

As bladder cancer treatment options expand, so do the challenges of delivering them in real-world practice. On this episode of BackTable Urology, community urologic oncologist Dr. Adam Gadzinski joins Dr. Ruchika Talwar to discuss how evolving therapies for non–muscle-invasive bladder cancer (NMIBC) are changing the landscape for both patients and providers. They explore the financial, logistical, and workflow hurdles to adopting new treatments in community settings, as well as the unique opportunities for expanding access through local clinical trials.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by

Urogen
https://www.zusduri.com

---

Timestamps

00:00 - Introduction
02:51 - Delivering Bladder Cancer Care in the Community
09:08 - Navigating Treatment Choices
13:05 - Patient Expectations and Insurance Coverage
19:01 - Ablation Strategies for Low and Intermediate Risk
22:34 - Making Therapies Community Friendly
27:12 - Launching Community Trials
31:08 - Referrals and Community Practice Advice
36:36 - Cystectomy Counseling Pearls
44:46 - Closing Takeaways

---

More about this episode

The conversation covers decision-making for bladder-preserving therapies, radical cystectomy, and trimodal approaches, along with strategies for guiding patients through these complex choices. Dr. Gadzinski shares insights on navigating insurance, launching community trials, and sustaining practice growth while maintaining high-quality care. The episode also offers practical advice on referrals, patient counseling, and finding the right practice environment for long-term success in bladder cancer care.

---

Resources

Bladder Cancer Basics Handbooks
https://bcan.org/bladder-cancer-basics-handbook/

Wellprept
https://wellprept.com/foundation

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

What opportunities and challenges does private equity bring to urology practices, and how can physicians engage in ways that strengthen their practice and preserve clinical priorities? On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Benjamin Lowentritt of Chesapeake Urology and United Urology Group to unpack the realities of private equity involvement in medicine. They discuss the motivations behind consolidation, the role of management services organizations, and strategies for building mutually beneficial partnerships while upholding physician autonomy and patient care.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps

00:00 - Introduction
02:58 - Why Urology Drew Private Equity
07:06 - Bad Headlines vs. Reality
11:14 - MSOs and Contracts Explained
15:24 - Timelines and After Private Equity
22:47 - Efficiency and Autonomy Fears
27:15 - Why Private Equity Gets Vilified
31:23 - Young Urologist Job Market
35:42 - Advice for New Grads
40:26 - Urology in 2035 and Fair Critiques of Private Equity
44:40 - Closing Thoughts

---

More about this episode

Dr. Lowentritt outlines the history of private equity in healthcare, noting that consolidation predated private equity and was driven by payer and hospital market power, reimbursement pressure, administrative burden, staffing, and capital needs. He distinguishes private equity’s role in hospitals from physician practice management, describing management services organization (MSOs) as structures that handle back-office functions and provide capital while preserving physician control over patient care and local governance. He also discusses private equity’s limited investment timeline, shaped by the ultimate goal of selling a profitable company, and potential end-states such as acquisition or public ownership, reflecting on his own experiences with United Urology’s acquisition. The conversation further explores recruiting new graduates, evolving partner tracks, mentorship, and maintaining physician leadership to preserve independent practice.

---

Resources

Dr. Benjamin Lowentritt is the current treasurer of LUGPA (Large Urology Group Practice Association) https://www.lugpa.org/, the Chesapeake Urology group (https://chesuro.com/), and United Urology Group (which was acquired by One Oncology

https://www.oneoncology.com/UnitedUrologyGroup/). One Oncology eventually was acquired by Cencora (https://www.cencora.com/).
Dr. Benjamin Lowentritt email: [email protected]

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in clinical practice.

---

Get the BackTable app
https://www.backtable.com/app

---

This podcast is supported by an educational grant from Pfizer.

---

Timestamps

00:00 - Introduction
02:51 - PARPi Basics
14:12 - Major Study Differences
19:00 - Timing and Selection of PARPi Combinations
26:39 - Case: Somatic BRCA2 loss and mHSPC
35:51 - Case Continued: BRCA2 Reversion
39:57 - BRCAAway Study
42:59 - Takeaways from the 2026 APCCC

---

More about this episode

The conversation reviews lessons learned from major clinical trials, including PROpel, MAGNITUDE, TALAPRO-2, and AMPLITUDE, and addresses how these studies inform real-world treatment choices. The doctors dig into case examples, such as BRCA2 loss and reversion, and highlight practical strategies for using germline and somatic testing to personalize care. Key insights from the 2026 Advanced Prostate Cancer Consensus Conference are also shared, emphasizing the importance of precision medicine in this rapidly evolving field.

---

Resources

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel) https://clinicaltrials.gov/study/NCT03732820

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) https://clinicaltrials.gov/study/NCT03748641?tab=study

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2) https://clinicaltrials.gov/study/NCT03395197

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) https://clinicaltrials.gov/study/NCT04497844

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm) https://pubmed.ncbi.nlm.nih.gov/39115414/

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app

Is pelvic lymph node dissection still necessary in the era of PSMA PET imaging? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Kirsten Greene about how advanced imaging is influencing decisions for radical prostatectomy. They examine the strengths and limits of PSMA PET, the risks and benefits of PLND, and why careful, evidence-based decision-making remains essential.

---

Get the BackTable app
https://www.backtable.com/app

---

Timestamps

00:00 - Introduction
03:12 - Risk Calculators and Consent
04:39 - Nomograms vs. Complications
09:57 - Endpoints That Matter
11:38 - PSMA PET Strengths and Limits
13:51 - Negative PET Decision-Making
15:08 - Positive PET and Multimodal Care
18:02 - Fluorescence Guided Surgery
19:10 - Counseling on Complications
22:27 - Preventing Lymphocele
24:56 - How Lahey Wrap Works
26:45 - Future Mapping and Therapy
28:47 - Research Gaps and Dogma
31:07 - Key Pearls and Wrap Up

---

More about this episode

Dr. Greene explains her approach using MSK and Briganti nomograms alongside PSMA PET, noting that PET scans may miss small nodal disease and quality varies between centers. She emphasizes PLND as a staging tool rather than a curative procedure, outlining potential complications like lymphocele, lymphedema, vascular and ureteral injury, and neuropraxia. The episode highlights her shared decision-making process, surgical techniques for limiting risk, and the importance of multimodal planning, especially for PET-positive nodal disease. Dr. Greene also shares practical tips for lymphocele prevention, including the use of metal clips and the Lahey wrap.

---

Resources

Different lymph node dissection ranges during radical prostatectomy for patients with prostate cancer: a systematic review and network meta-analysis
https://pubmed.ncbi.nlm.nih.gov/36872312/

Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33865797/

---

BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists.

Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.

► https://www.backtable.com/app